Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospectively Randomized Phase III Trial, Studying the Benefits of Adjuvant Sequential vs. Combined Taxane Based Chemotherapy, Followed by Different Biological Treatment Strategies in Early, HER2-positive Breast Cancer

Next Previous
Trial Profile

Prospectively Randomized Phase III Trial, Studying the Benefits of Adjuvant Sequential vs. Combined Taxane Based Chemotherapy, Followed by Different Biological Treatment Strategies in Early, HER2-positive Breast Cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Docetaxel (Primary) ; Gemcitabine (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil; Goserelin; Letrozole; Tamoxifen
  • Indications Early breast cancer; HER2 positive breast cancer
  • Focus Therapeutic Use
  • Acronyms SUCCESS-B

Most Recent Events

  • 06 Jun 2012 New source identified and integrated (German Clinical Trials Register, DRKS00003641).
  • 02 Apr 2012 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
  • 02 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top